Genetic testing reads your DNA to find changes linked to inherited disease, carrier status, or how your body handles certain medicines. Unlike a routine blood test, which measures what is happening in your body now, the result is fixed from birth and does not change. The main types are hereditary cancer and heart panels, carrier screening before pregnancy, pharmacogenomic tests, broad genome sequencing, and consumer ancestry kits. Choosing the right type matters more than any brand.
The types, and what each one answers
Hereditary cancer panels look at genes such as BRCA1, BRCA2, PALB2, CHEK2, and the Lynch syndrome genes. They answer whether you inherited a higher risk of breast, ovarian, colorectal, pancreatic, or prostate cancer, which changes how early and how often you screen. Our guide to cancer genetic testing covers who qualifies.
Cardiac panels cover inherited heart muscle and rhythm conditions, familial high cholesterol, and aortic disease. A positive result usually prompts testing of close relatives, since these conditions can cause sudden events in people who feel well.
Carrier screening checks whether you carry a condition you could pass to a child without having it yourself, such as cystic fibrosis or spinal muscular atrophy. Professional groups now recommend offering it to everyone planning a pregnancy. See genetic testing before pregnancy.
Pharmacogenomic tests look at the genes that process medicines, including several antidepressants, blood thinners, pain drugs, and statins. The result tells a prescriber whether a standard dose is likely to work, fail, or cause side effects in you.
Whole-exome and whole-genome sequencing read most or all of your DNA at once, for undiagnosed conditions and, increasingly, for healthy adults who want a full picture. The caveat is that they find many changes whose meaning is not yet known.
Consumer kits, the kind that arrive in the mail, do ancestry and traits well. For health, they check a short list of known variants rather than reading whole genes.
What a result can and cannot tell you
A clinical test can identify a specific inherited condition with high accuracy, tell you whether you carry something your children could inherit, and predict how you will respond to certain drugs.
What it cannot do is predict most common diseases with any certainty. Type 2 diabetes, high blood pressure, and most heart disease come from many genes acting together with diet, weight, smoking, and age. Polygenic risk scores give a probability for some of these, not a diagnosis, and a lipid panel tells you more about today's heart risk than a risk score does.
It also cannot detect cancer. A hereditary cancer panel finds inherited risk; imaging, biopsy, and screening find cancer itself.
Clinical versus consumer tests
This is the distinction that matters most. Clinical tests are run by laboratories certified under CLIA and usually accredited by CAP, ordered through a clinician, and interpreted with your personal and family history, often alongside a genetic counselor. They sequence entire genes and classify every change they find.
Consumer kits check a fixed set of variants chosen in advance. For BRCA, a well-known kit tests a handful of variants out of thousands that cause disease, so a negative result means you do not carry those particular variants, not that your BRCA genes are clear. A strong family history, or a kit that flags anything, calls for clinical testing rather than treating the kit as the last word.
Who should consider genetic testing
The strongest reason is family history. Breast or ovarian cancer in a close relative under 50, several relatives with the same cancer, colorectal cancer at a young age, sudden cardiac death in a relative, or a known variant in the family all qualify for clinical testing, and most insurers cover it when criteria are met.
Anyone planning a pregnancy is a candidate for carrier screening, since most carriers have no family history at all.
People who have had unexplained side effects or poor responses to several medications may benefit from pharmacogenomic testing, and the result is useful for life.
Healthy adults with no family history and no specific question are the hardest case. Broad sequencing can find actionable variants, but it also finds uncertainty, and the decision is best made with a counselor.
Reading your result
Results come in three forms, and each means something different.
A positive result, reported as a pathogenic or likely pathogenic variant, means increased risk or confirmed carrier status. It is not a diagnosis of disease. It leads to a plan: earlier or more frequent screening, preventive options, and testing for relatives, who each have a 50 percent chance of sharing a dominant variant.
A negative result means no harmful variant was found in the genes tested. If your family has a known variant and you do not carry it, that is strongly reassuring. If your family history is strong but no variant has been identified in anyone, a negative is less conclusive, because the cause may lie in a gene the panel did not cover.
A variant of uncertain significance, or VUS, is a change whose effect is not yet known. These are common; studies report them in 15 to 32 percent of people having hereditary cancer panels. Guidelines are clear that a VUS should not change your medical care, and most are later reclassified as harmless. The lab will usually contact you if the classification changes.
Privacy, insurance, and cost
The Genetic Information Nondiscrimination Act, signed in 2008, bars health insurers and most employers from using genetic results against you. It does not cover life insurance, disability insurance, or long-term care insurance, and MedlinePlus notes that other protections vary by circumstance. If you are planning to apply for any of those, it is worth thinking about timing before you test.
Read a lab's data policy before sending a sample. Clinical labs are bound by medical privacy law; consumer companies set their own terms, and some share de-identified data with partners. Cost ranges from modest for a single-gene or pharmacogenomic test to several times that for sequencing.
How to get tested
Through a clinician, a genetics clinic, or directly. August's lab tests list clinical genetic tests from accredited laboratories, with turnaround and price shown before you order. A phlebotomist draws the sample at home or you visit a nearby lab, a clinician reviews every result, and genetic counseling can be arranged for disease-risk findings. August Care members get up to 50 percent off next-day lab tests and a first consultation included.
If you are not sure which type of test fits your question, you can describe your situation to August, a free AI health assistant, to help think it through. It is a starting point, not a diagnosis.
Frequently Asked Questions
Whether you inherited a higher risk of certain cancers or heart conditions, whether you carry a condition you could pass to a child, and how your body processes specific medications. Clinical tests answer these with high accuracy. They cannot predict most common diseases with certainty or detect a cancer that is already present.
Clinical tests identify known variants with very high accuracy. The uncertainty lies in interpretation: some changes have no established meaning yet, and those are reported as variants of uncertain significance. Consumer kits are accurate for the variants they check but test far fewer, so a negative kit result is not a clean bill of health.
If you have a family history of early cancer, heart disease, or an inherited condition, are planning a pregnancy, or have reacted badly to several medications, it is worth discussing with a clinician. For healthy adults with no specific question, the decision is more personal and benefits from a conversation with a genetic counselor.
Clinical tests sequence whole genes in accredited labs with professional interpretation. Consumer kits check a short list of known variants and can miss most disease-causing changes. For ancestry and curiosity, kits work well. For disease risk, clinical testing is the standard.
It means the lab found a change in a gene but does not yet know whether it affects health. It is not a positive result and should not change your care. Most are later reclassified as benign, and labs typically notify you if the classification changes.
Health insurers and most employers cannot use them against you under GINA, the federal law passed in 2008. Life, disability, and long-term care insurers are not covered by that law, so some people arrange those policies before testing, and it is worth asking a counselor about timing.
One to four weeks for most panels and carrier screening, one to two weeks for pharmacogenomic tests, and six to twelve weeks or more for exome or genome sequencing, which involves far more data and interpretation. The catalog shows the expected turnaround for each test before you order.
Yes. Clinical genetic tests use a standard blood sample, which an August phlebotomist can draw at home, or a saliva kit in some cases. The sample goes to an accredited lab, and a clinician reviews the result with you, with counseling available for disease-risk findings.
